Neurocrine Biosciences | NBIX - Ebit



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.37B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


Ebit 更改 日
AbbVie USD 6.72B 1.99B 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Exelixis USD 248.41M 2.93M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Incyte USD 700.4M 356.23M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pfizer USD -180M 5.16B 2026-06
Prothena USD 25.79M 53M 2026-03
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Repligen USD 21.13M 1.15M 2026-06
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06